Review articleRefractory asthma
Section snippets
Definition
Refractory asthma describes a small subset of asthmatic patients with disease that is unresponsive to standard therapies, in particular corticosteroids. Severe asthma, as defined in the National Heart, Lung, and Blood Institute Guidelines on the treatment of asthma, refers to disease that is characterized by continual symptoms, frequent nocturnal exacerbations, and severe airflow obstruction [3].
A key feature in the definition of refractory asthma is the presence of airflow obstruction that is
Diagnosis
The term refractory asthma can only be applied to individual patients in whom the diagnosis of asthma is certain. Airflow obstruction is a feature of many diseases other than asthma, including chronic obstructive pulmonary disease; emphysema from other causes, such as α1-antitrypsin deficiency; cystic fibrosis; allergic bronchopulmonary aspergillosis; vasculitis (Churg-Strauss syndrome); and chronic eosinophilic pneumonia. Even after asthma has been diagnosed, there are a number of comorbid
Prevalence
Although asthma affects almost 10% of the general population, refractory asthma accounts for about 5% of all patients with asthma [17]. Furthermore, the exact prevalence of this disease is limited by the variety of terms used when describing this phenomenon and the lack of a standardized definition. Despite the fact that severe, refractory asthma affects a small minority of asthma patients, these individuals are an important subset because their quality of life is disproportionately affected,
Pathology of severe asthma
In addition to the variations seen among clinical phenotypes of severe asthma, some investigators have described pathologic features that correspond to clinically distinct patterns. For example, Wenzel et al [18] have reported two pathologically distinct subgroups of patients with severe asthma: one group with a pulmonary parenchyma predominance of eosinophils and one with eosinophil numbers equivalent to normal controls. In this study, patients with clinically severe asthma were compared with
Mechanisms of action of corticosteroids in asthma
Most asthmatic patients are responsive to the anti-inflammatory properties of corticosteroids. After entering the cell, corticosteroid molecules bind to a glucocorticoid receptor (GCR) in the cytoplasm. After the loss of the heat shock protein subunits, the glucocorticoid-GCR (GC-GCR) complex becomes activated and translocates to the nucleus where it may modulate expression of a number of genes. First, the GC-GCR binds to a glucocorticoid response element (GRE), which is located upstream from a
Treatment
An increased understanding of the pathogenesis of asthma, including refractory asthma, has directed therapeutic efforts to new approaches. Refractory asthma patients require a more aggressive approach to control of their disease and to limit irreversible loss of pulmonary function. The unfortunate requirement of these patients for large doses of corticosteroids places refractory asthma patients at increased risk for adverse effects of this treatment. Because of this risk and the need for an
Summary
Treating patients with refractory asthma remains an ongoing challenge. Although most patients respond to large doses of systemic corticosteroid, the adverse effects associated with such a treatment limit its general use. Clinicians treating patients with refractory asthma must consider tapering systemic corticosteroid at every opportunity. Recent advances in the understanding of the pathogenesis of refractory asthma and corticosteroid resistance have fueled further study in the mechanisms of
References (60)
- et al.
Corticosteroid resistance in mild asthma: markers of persistent inflammation
Ann Allergy Asthma Immunol
(1999) - et al.
Rhinosinusitis in severe asthma
J Allergy Clin Immunol
(2001) Gastroesophageal reflux and asthma: insight into the association
J Allergy Clin Immunol
(1999)Complications of allergic rhinitis: implications for sinusitis and asthma
J Allergy Clin Immunol
(1998)- et al.
Steroid-resistant asthma: immunologic and pharmacologic features
J Allergy Clin Immunol
(1992) - et al.
Corticosteroid pharmacokinetics in asthma
Lancet
(1990) - et al.
In vivo resistance to corticosteroids in bronchial asthma is associated with enhanced phosphorylation of JUN N-terminal kinase and failure of prednisolone to inhibit JUN N-terminal kinase phosphorylation
J Allergy Clin Immunol
(1999) - et al.
The effects of glucocorticoids on phorbol ester and cytokine stimulated transcription factor activation in human lung
Life Sci
(1994) - et al.
Glucocorticoid-mediated repression of NF kappa B activity in endothelial cells does not involve induction of IkappaBalpha synthesis
J Biol Chem
(1996) - et al.
The role of viral infections in the natural history of asthma
J Allergy Clin Immunol
(2000)
T cell responses to Mycoplasma pneumoniae (MP) in patients with chronic asthma
J Allergy Clin Immunol
Molecular mechanisms of decreased steroid responsiveness induced by latent adenoviral infection in allergic lung inflammation
J Allergy Clin Immunol
Management of steroid-dependent asthma with methotrexate: a meta- analysis of randomized clinical trials
Respir Med
Low-dose methotrexate spares steroid usage in steroid-dependent asthmatic patients: a meta-analysis
Chest
The role of methotrexate in the management of steroid-dependent asthma
Chest
Randomised, double-blind, placebo-controlled trial of methotrexate in steroid-dependent asthma
Lancet
Effect of intravenous immunoglobulin on steroid consumption in patients with severe asthma: a double-blind, placebo-controlled, randomized trial
J Allergy Clin Immunol
A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma
Clin Immunol
Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial
Lancet
Steroid resistance in bronchial asthma
Ann Intern Med
Corticosteroid resistance in chronic asthma
BMJ
National Asthma Education and Prevention Program. Exper Panel Report 2: guidelines for the diagnosis and management of asthma. National Institutes of Health Publ No 97-4051
Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma
Eur Respir J
Proceedings of the ATS workshop on refractory asthma. Current understanding, recommendations, and unanswered questions. American Thoracic Society
Am J Respir Crit Care Med
Relationship between asthma and gastro-oesophageal reflux: significance of endoscopic grade of reflux oesophagitis in adult asthmatics
J Gastroenterol Hepatol
Severe steroid-dependent asthma with IgG-2 deficiency and recurrent sinusitis: response to treatment with high-dose intravenous immunoglobulin
Allergol Immunopathol (Madr)
Cardiac asthma presenting as status asthmaticus: deleterious effect of epinephrine therapy
Intensive Care Med
Clinical features of vocal cord dysfunction
Am J Respir Crit Care Med
The respiratory muscles
N Engl J Med
Cited by (7)
Dyspnea
2006, Medical Clinics of North AmericaCitation Excerpt :Airway obstruction may be organic, occurring as a result of laryngeal tumors, polyps, or vocal cord paralysis, or be caused by functional vocal cord disorders, such as paradoxical vocal cord movement. Dyspnea and stridor are common features, and visualization of the glottis may be needed to diagnose the obstruction [1,44]. Patients who have neuromuscular diseases resulting in acute weakness, such as Guillain-Barré syndrome or myasthenia gravis, will report dyspnea because they may be using a much greater percentage of their respiratory strength than previously to accomplish thoracic expansion and diaphragmatic excursion.
Internet-based tapering of oral corticosteroids in severe asthma: A pragmatic randomised controlled trial
2011, ThoraxCitation Excerpt :This article provides a detailed description of the internet-based management tool that is not only ideal for use in clinical practice, but also suitable to assess outcome in clinical trials with novel anti-inflammatory steroid-sparing drugs. Tapering oral corticosteroids in patients with severe asthma remains a challenge.7 These patients-although relatively few-generally require considerable time and resources because their disease is often complicated by comorbidities,8 steroid resistance9 and fixed airflow limitation.10
Immunoglobulin E-mediated airway inflammation is active in most patients with asthma
2007, Journal of the American Academy of Nurse PractitionersNew approach in asthma treatment using excitatory modulator
2007, Phytotherapy ResearchAsthma: Versatile treatment for a variable disease
2005, Journal of Asthma